AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02131194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sugar pill manufactured to mimic Lenstatin
Study NCT02380781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information in the form of a video
Description: see intervention description
Study NCT01001377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Administered by intravenous infusion
Study NCT01001377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered by intravenous infusion
Study NCT04442867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management
Description: Based on the clients' problems, individualized and specific health education such as recognition of the early signs and symptoms of an exacerbation or deterioration of disease condition, the frequency, dosage, duration of each health-promoting activity that was of therapeutic value, and the techniques required to perform these activities will be provided by the Nurse Case Manager.
Study NCT04442867 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Social call
Description: Provide social call to participants, such as ask the participants what TV program do you like most, and how are you recently.
Study NCT01342302 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychosocial Intervention for Couples
Description: Intervention delivered on line
Study NCT04535700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Description: Patients receive 30 mg/day of pioglitazone for the entire period they remain in hospital
Study NCT04535700 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard of care
Description: Patients receive the standard of care, according to the hospital protocol for patients with type 2 diabetes mellitus hospitalized.
Study NCT01119794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab and Bortezomib
Description: Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
Study NCT04320654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The aim of this intervention is to increase patients average daily step count. The walking program is a behavior change intervention in which the pedometer will be used as a tool to help the patients monitor their activity levels.
Study NCT01532310 — intervention group
Intervention type: DRUG
Intervention: belimumab
Description: Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
Study NCT03385902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optimal start time
Description: patients will start hemodialysis when their DIFE reach 35, and can not wait if the DIFE decline to 30.
Study NCT04164316 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Kinesio Tape
Description: Kinesio TexTM Tape which is the original elastic therapeutic adhesive tape which is a latex-free, hypoallergenic, waterproof, porous.
Study NCT04164316 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tape
Description: Kinesio TexTM Tape which is the original elastic therapeutic adhesive tape which is a latex-free, hypoallergenic, waterproof, porous.
Study NCT03385902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: late start time
Description: patients will start hemodialysis when their DIFE less than 30
Study NCT02134795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TNM (trade name), a form of brainstem Stimulation
Description: The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes. The stimulation is non-invasive and non-electrical. The form of stimulation acts on the brainstem.
Study NCT01696994 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01696994 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening Questionnaire Administration
Description: Undergo questionnaire assessments
Study NCT01696994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Imaging
Description: Undergo TVU
Study NCT03406871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: One course will last 28 days. Oral administration for 21 consecutive days, with a 1-week washout period. As for the expansion cohort, implemented using the RD estimated in the dose-escalation cohort.
Study NCT00732576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menaquinone-7
Description: capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
Study NCT01651377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole
Description: Participants will receive pramipexole ER 0.375, .075, 1.5, 2.25, and 3mg/d in an ascending-dose pattern.
Study NCT01651377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
Study NCT04525378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell-based therapy
Description: Intravenous administration of MSCs, performed as single dose (high dose group) or repeated after 48 h (low doses; intermediate dose)
Study NCT03853408 — intervention group
Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Cholecystectomy (removal of the gallbladder) for acute cholecystitis
Study NCT01461603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vamin (Fresenius Kabi)
Description: Vamin 18gN 1ml/min infusion in 6 hours
Study NCT01461603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3hydroxybutyrate
Description: Goldbio, FFA-3OHB, dry powder mixed with sterile water at Aarhus University hospital pharmacy.
Study NCT00937326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
Study NCT00937326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
Study NCT02589743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sealant
Description: Application of preventive agent
Study NCT02589743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhesive and Sealant
Description: Application of preventive agent and technique for control moisture
Study NCT03785470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose and physical inactivity
Description: Subjects will drink 6 cans of regular sodas daily (divided throughout the day) and will decreased physical activity to less than 5000 steps daily for 10 days.
Study NCT01529619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Study NCT00479167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib and Tositumomab I-131
Study NCT03417505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral lenses treated with Tangible Hydra-PEG
Description: Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.
Study NCT03417505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Untreated scleral lenses
Description: Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.
Study NCT00732576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: 9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks
Study NCT03796195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: .5% Bupivacaine
Description: Ultrasound guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
Study NCT02455362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
Study NCT00732576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: krill oil
Description: 9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
Study NCT02455362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02663180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational program
Description: Educational strategies: 2 Lecture about depression 30 minutes supported by group discussion, brochures and display of posters with mental-health slogans on depression in the schools.
Study NCT02663180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video contact
Description: Contact strategies: Investigators will show a video of a young male who had been diagnosed with depression. The video presented information that was moderately disconfirming of prior stereotypes by balancing the individual's difficulties resulting from Depression, with his ability to live a normal life.
Study NCT03510780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery with Enamel Matrix Derivative
Description: Patients will be treated by periodontal surgical flaps with the addition of EMD + bone graft
Study NCT03510780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery with Platlet Rich fibrin
Description: Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
Study NCT04620135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil ophthalmic solution 0.02%
Description: Topical sterile ophthalmic solution Other Name: Rhopressa®
Study NCT04620135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ripasudil hydrochloride hydrate ophthalmic solution 0.4%
Description: Other Name: Glanatec®
Study NCT01448486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Oral raltegravir, 400 mg tablet, twice daily for one year.
Study NCT00777608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo 5mg (run in)
Description: Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
Study NCT00777608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo 5mg (run in)
Description: Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
Study NCT00777608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 5 - 10 mg
Description: Donepezil 1 capsule (5 mg) orally, once daily for 14 days.~Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).
Study NCT00777608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo 5-10 mg
Description: Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.~Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).
Study NCT04056286 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 45 g whey protein + 20 g maltodextrin
Study NCT04056286 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-OHB/whey
Description: 50 g 3-OHB + 45 g whey protein + 20 g maltodextrin
Study NCT00777608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Description: Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
Study NCT00777608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil 10 mg
Description: Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
Study NCT02109380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Study NCT01594983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCQ908
Study NCT03318731 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Taken orally in capsule form
Study NCT03318731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fenugreek Extract, Low Dose
Description: Taken orally in capsule form
Study NCT03318731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fenugreek Extract, High Dose
Description: Taken orally in capsule form
Study NCT03630250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N. lactamica
Description: Genetically modified N. lactamica
Study NCT03473626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alicaforsen
Description: Alicaforsen tablet
Study NCT04105322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: The kinesio tape is adhesive and it does not contain drug substance. After the patients were randomized to the groups, kinesio tape will be applied to the relevant region.
Study NCT03510910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: acetaminophen 600 mg to be taken every 8 hours (TID)
Study NCT03510910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percocet
Description: Oxycodone/acetaminophen (Percocet) 5 mg/325 mg as needed for breakthrough pain for patients in Percocet+ Acetaminophen group.~Percocet Group will receive standard of care Percocet 5 mg/325 mg every 6 hours PRN
Study NCT04247789 — intervention group
Intervention type: OTHER
Intervention: Self-reported questionairres
Description: the fatigue will be determined through self reported questionnairres
Study NCT01594983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Study NCT01594983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Fenofibrate once daily 12 weeks
Study NCT01594983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Fish Oil once daily for 12 weeks
Study NCT04180631 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound imaging parameter (QUS)
Description: Quantitative ultrasound imaging parameters (QUS) are analyzed to evaluate hepatic steatosis
Study NCT01064752 — intervention group
Intervention type: DRUG
Intervention: Minocycline
Description: 100 mg po bid for 8 weeks
Study NCT02728570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Dietary Flavonoids
Description: A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing high levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
Study NCT03406871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: One course will last 28 days. Given once every 2 weeks at a dose of 3.0 mg/kg.
Study NCT02728570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Dietary Flavonoids
Description: A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing low levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
Study NCT02092467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: Oral tablet, 5 mg BID
Study NCT01594983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of LCQ908
Description: Matching placebo of LCQ908
Study NCT01594983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCQ908
Description: Matching placebo of LCQ908
Study NCT04588298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: AZD9833 tablets will be administered orally.
Study NCT01594983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of LCQ908
Description: Matching placebo of LCQ908
Study NCT01594983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of fenofibrate
Description: Matching placebo of fenofibrate
Study NCT01594983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of fenofibrate
Description: Matching placebo of fenofibrate
Study NCT01594983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of fenofibrate
Description: Matching placebo of fenofibrate
Study NCT01594983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of fish oil
Description: Matching placebo of fish oil capsule
Study NCT01594983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of fish oil
Description: Matching placebo of fish oil capsule
Study NCT01594983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of fish oil
Description: Matching placebo of fish oil capsule
Study NCT04339439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vessel loop (FDA product code FZZ)
Description: The intervention will be a vessel loop placed below sutures to raise the sutures from the skin of the palm.
Study NCT00779701 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: Insulin infusion titrated to patients blood glucose to maintain blood glucose between 80-110mg/dL
Study NCT04568070 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mini-BESTest (Mini-Balance Evaluation Systems Test)
Description: Balance evaluation test that has 14 tasks leading to a total possible score of 28 points requires only 10 to 15 minutes to conduct.
Study NCT04568070 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale
Description: The scale is a 14-item objective measure designed to assess static balance and fall risk in adult populations.
Study NCT04568070 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Timed Up and Go Test
Description: It is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
Study NCT04568070 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional Reach Test
Description: The Functional Reach Test is a single item test developed as a quick screen for balance problems in older adults. A score of 6 or less indicates a significant increased risk for falls. A score between 6-10 inches indicates a moderate risk for falls.
Study NCT01145443 — intervention group
Intervention type: OTHER
Intervention: Alternative Intensivist staffing models.
Description: During the study period, each participating ICU alternated between two distinct intensivist staffing formats: (i) in the Discontinuous arm of the study, there was a weekend cross-coverage format wherein an intensivist was responsible for care for a two week or half-month block, but colleagues covered the weekends within each block, or (ii) in the Continuous arm of the study, there was an uninterrupted staffing format, wherein a single intensivist was responsible for the entire two week, or half-month, period. In each ICU the study interval was divided into three phases, so that the models alternated twice in each ICU, beginning with either the weekend cross-coverage or the uninterrupted staffing formats, the four hospitals were randomly assigned between these two patterns.
Study NCT00844714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: 1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study
Study NCT03039283 — intervention group
Intervention type: DEVICE
Intervention: Nucleus CI532 cochlear implant
Description: Retrospective study of the commercial CI532 cochlear implant
Study NCT02469753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDs
Description: continuous daily
Study NCT02469753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAIDs
Description: on demand
Study NCT02469753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-TNF
Study NCT02469753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-TNF
Study NCT02614586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058
Description: TAK-058 oral solution.
Study NCT02614586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron capsule.
Study NCT03950960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days
Study NCT03950960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days
Study NCT00946023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -6 through -2: 30 mg/m\^2 IV daily
Study NCT00946023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -6 and -5: 14.5 mg/kg IV daily; Days 3 and 4: 50 mg/kg IV daily
Study NCT00946023 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Day -1: 200 centigray (cGy) in a single fraction